Tag: nasdaq:admp

August 28, 2019

Adamis Pharmaceuticals Provides Launch and Marketing Update

Adamis Pharmaceuticals (NASDAQ:ADMP) has announced a progress report and marketing update for the US launch of SYMJEPI injections. As quoted...
January 17, 2019

Adamis’ Commercial Partner Launches SYMJEPI (epinephrine) in the US

Adamis Pharmaceuticals (NASDAQ:ADMP) today announced that its marketing and commercial partner, Sandoz, a Novartis division, has launched SYMJEPI (epinephrine) 0.3 mg...
January 2, 2019

Adamis Submits NDA for New Product

The application was for Adamis’ naloxone pre-filled single dose syringe (PFS) product candidate, as a treatment for opioid overdose.
January 2, 2019

Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone Pre-Filled Syringe

Adamis Pharmaceuticals (NASDAQ:ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for...
December 6, 2018

Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI

Adamis Pharmaceuticals (NASDAQ:ADMP) today provided a business update announcing the U.S. launch of FDA-approved SYMJEPI (epinephrine) 0.3mg Injection is planned for...
October 7, 2018

5 Top Weekly NASDAQ Biotech Stocks: vTv Leads with 374 Percent

vTv Therapeutics, Trevena, Cyclacel Pharmaceuticals, Paratek Pharmaceuticals and Avadel Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index.
July 23, 2018

Adamis Pharmaceuticals Adds Sublingual Erectile Dysfunction Product Candidate to its Pipeline

Adamis Pharmaceuticals (NASDAQ:ADMP) has announced the addition ofa  sublingual erectile dysfunction product candidate to its pipeline called Tadalafil. As quoted...